Claudia Diamonte
Overview
Explore the profile of Claudia Diamonte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mailankody S, Devlin S, Landa J, Nath K, Diamonte C, Carstens E, et al.
N Engl J Med
. 2022 Sep;
387(13):1196-1206.
PMID: 36170501
Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5,...
2.
Pennisi M, Sanchez-Escamilla M, Flynn J, Shouval R, Tomas A, Silverberg M, et al.
Blood Adv
. 2021 Aug;
5(17):3397-3406.
PMID: 34432870
Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation...
3.
Adusumilli P, Zauderer M, Riviere I, Solomon S, Rusch V, OCearbhaill R, et al.
Cancer Discov
. 2021 Jul;
11(11):2748-2763.
PMID: 34266984
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I...
4.
Wudhikarn K, Flynn J, Riviere I, Gonen M, Wang X, Senechal B, et al.
Blood
. 2021 Apr;
138(7):531-543.
PMID: 33851211
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority...
5.
Perica K, Flynn J, Curran K, Rivere I, Wang X, Senechal B, et al.
Leukemia
. 2021 Mar;
35(11):3268-3271.
PMID: 33686196
No abstract available.
6.
Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33335028
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients...
7.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T, et al.
Blood Adv
. 2020 Aug;
4(15):3776-3787.
PMID: 32780846
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell...
8.
Pennisi M, Jain T, Santomasso B, Mead E, Wudhikarn K, Silverberg M, et al.
Blood Adv
. 2020 Feb;
4(4):676-686.
PMID: 32084260
Various grading systems are currently used for chimeric antigen receptor (CAR) T-cell-related toxicity, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). We compared the recently proposed American...
9.
Halton E, Llerandi D, Diamonte C, Quintanilla H, Miale-Mayer D
Clin J Oncol Nurs
. 2017 Mar;
21(2 Suppl):35-40.
PMID: 28315556
Background: The introduction of chimeric antigen receptor (CAR) T-cell therapy has created challenges and opportunities for nurses. Clinical nurses must be educated on new treatment modalities to recognize toxicity symptoms...